-+ 0.00%
-+ 0.00%
-+ 0.00%

Propanc Biopharma CEO tours European CDMO GMP facility ahead of PRP production for Phase 1b study

PUBT·06/16/2026 12:45:20
Listen to the news
Propanc Biopharma CEO tours European CDMO GMP facility ahead of PRP production for Phase 1b study
  • Propanc Biopharma CEO James Nathanielsz toured a European CDMO’s GMP facility to prepare for PRP production tied to its Phase 1b first-in-human study.
  • Propanc aligned project timelines with the manufacturer, targeting preproduction in August 2026, an engineering run in October 2026, GMP manufacture from December 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160845PRIMZONEFULLFEED9747724) on June 16, 2026, and is solely responsible for the information contained therein.